| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-2 |
| Number of pages | 2 |
| Journal | Brain, Behavior, and Immunity |
| Volume | 73 |
| DOIs | |
| State | Published - Oct 2018 |
ASJC Scopus subject areas
- Immunology
- Endocrine and Autonomic Systems
- Behavioral Neuroscience
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Brain, Behavior, and Immunity, Vol. 73, 10.2018, p. 1-2.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Interleukin (IL)-6
T2 - A good kid hanging out with bad friends (and why sauna is good for health)
AU - Raison, Charles L.
AU - Knight, Jennifer M.
AU - Pariante, Carmine
N1 - Funding Information: Dr. Raison discloses that in the last twelve months he has served as a consultant to Usona Institute, Emory Healthcare, Alkermes and Novartis. This publication was supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Numbers UL1TR001436 and KL2TR001438. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Professor Pariante is supported by the UK National Institute for Health Research (NIHR) Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King's College London; and by the UK Medical Research Council, grants MR/L014815/1, MR/J002739/1 and MR/N029488/1; he has received research funding from pharmaceutical companies interested in the development of new antidepressants targeting immune mechanisms, such as Johnson & Johnson and Eleusis Ltd, but this amounts to less than 10% of his overall research funding. Moreover, he has received research funding from the Medical Research Council (UK) and the Wellcome Trust for research on depression and inflammation as part of two large consortia that also include Johnson & Johnson, GSK, Pfizer and Lundbeck. Funding Information: Dr. Raison discloses that in the last twelve months he has served as a consultant to Usona Institute, Emory Healthcare, Alkermes and Novartis. This publication was supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health , through Grant Numbers UL1TR001436 and KL2TR001438 . Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Professor Pariante is supported by the UK National Institute for Health Research (NIHR) Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King’s College London; and by the UK Medical Research Council , grants MR/L014815/1 , MR/J002739/1 and MR/N029488/1 ; he has received research funding from pharmaceutical companies interested in the development of new antidepressants targeting immune mechanisms, such as Johnson & Johnson and Eleusis Ltd, but this amounts to less than 10% of his overall research funding. Moreover, he has received research funding from the Medical Research Council (UK) and the Wellcome Trust for research on depression and inflammation as part of two large consortia that also include Johnson & Johnson, GSK, Pfizer and Lundbeck.
PY - 2018/10
Y1 - 2018/10
UR - http://www.scopus.com/inward/record.url?scp=85049046552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049046552&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2018.06.008
DO - 10.1016/j.bbi.2018.06.008
M3 - Review article
C2 - 29908964
AN - SCOPUS:85049046552
SN - 0889-1591
VL - 73
SP - 1
EP - 2
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
ER -